<DOC>
	<DOCNO>NCT02738047</DOCNO>
	<brief_summary>Pharmocogenomic test assessment medication regimen disease management patient drug know genetic variation .</brief_summary>
	<brief_title>Reduction Adverse Drug Events Readmissions</brief_title>
	<detailed_description>Pharmocogenomic . A multicenter , observational study evaluate use Pharmocogenomic test assessment medication regimen disease management patient drug know influenced genetic variation .</detailed_description>
	<criteria>INCLUSION CRITERIA Patients may include Study meet follow inclusion criterion : 1 . Male female patient 25 year age old able give write Informed Consent participate Clinical Study base voluntary agreement thorough explanation patient 's participation provide . 2 . Patient underwent PGx test allele appropriate target drug within prior 120 day ( `` index PGx test assessment '' ) ; 3 . Patient receive least one medication know associate allelic variation time ( `` index PGx test assessment '' ) , include overthe counter medication ; 4 . Patient history least one TDAE 24month period precede PGx test assessment , experienced inadequate efficacy target drug . EXCLUSION CRITERIA Patients exclude Study follow criterion apply : 1 . Patient currently hospitalize ; 2 . Patient 's medical medication history unavailable 120day period precede PGx test assessment ; 3 . Patient unable provide accurate history due mental Incapacity ; 4 . Patient known undergone prior PGx test gene specific target drug ( ) , exclusive PGx test relating Study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>